Literature DB >> 1296859

Effects of deoxycorticosterone acetate on glucose metabolism in nondiabetic and streptozotocin-diabetic rats.

S Dai1, H Fraser, J H McNeill.   

Abstract

A previous study in our laboratory showed that streptozotocin (STZ) induced diabetic, deoxycorticosterone acetate (DOCA) induced hypertensive rats exhibited significantly lower levels of plasma glucose than did normotensive diabetic animals. The present experiments further investigate the effects of DOCA treatment on fasting levels of plasma glucose and insulin and on their changes after oral glucose challenge in nondiabetic and STZ-diabetic rats. It was found that, in nondiabetic rats, DOCA-induced hypertension was associated with normal glucose levels and glucose tolerance but with significantly lower levels of plasma insulin. DOCA-treated diabetic animals showed significantly lower levels of plasma glucose, but their plasma insulin concentrations were not significantly different from those of the DOCA vehicle treated diabetic rats. DOCA-treated diabetic rats also had significantly higher plasma levels of cholesterol and triglycerides. It is suggested that DOCA may have a direct or indirect action on the assimilation, production, or utilization of glucose, perhaps leading to an improvement in insulin sensitivity and subsequently a decrease in insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1296859     DOI: 10.1139/y92-207

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

1.  In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess.

Authors:  J Campión; V Lahera; V Cachofeiro; B Maestro; N Dávila; M C Carranza; C Calle
Journal:  Mol Cell Biochem       Date:  1998-08       Impact factor: 3.396

2.  New insights on hyperglycemia in 17-hydroxylase/17,20-lyase deficiency.

Authors:  Lingling Xu; Lin Lu; Anli Tong; Shi Chen; Wei Li; Huabing Zhang; Fan Ping; Yuxiu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.